News

Congratulate to ProteLight for Being Identified as Hi-Tech Enterprise

2017-12-10

On December7th, 2017, through strict appraisal by relevant higher authorities that Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. was identified as Hi-Tech Enterprise, which strongly suggests that the government confirm ProteLight taking national category 1.1 new drug development as direction over the years, which is also an important signal of ProteLight’s technical level and products technology.

Previous article

ProteLigt R & D Team was named as “Innovation and Entrepreneurship Team” of Jiangsu Province in 2017

Next article

ProteLight Pharma Held a Grand-breaking Ceremony of New Plant Construction

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China